![New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/3676067f-cd6a-49b8-9e03-e25569ed203c/gr2_lrg.jpg)
New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies - Journal of Hepatology
![Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms | Journal of Interferon & Cytokine Research Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms | Journal of Interferon & Cytokine Research](https://www.liebertpub.com/cms/10.1089/jir.2012.0120/asset/images/medium/figure1.gif)
Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms | Journal of Interferon & Cytokine Research
![Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML](https://www.mdpi.com/pharmaceuticals/pharmaceuticals-03-00994/article_deploy/html/images/pharmaceuticals-03-00994-g001.png)
Pharmaceuticals | Free Full-Text | Antiproliferative Properties of Type I and Type II Interferon | HTML
![Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - International Journal of Infectious Diseases Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - International Journal of Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9a35320e-8bf8-4394-aa83-db59f278d0bb/gr1_lrg.jpg)
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - International Journal of Infectious Diseases
![Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrgastro.2010.101/MediaObjects/41575_2010_Article_BFnrgastro2010101_Fig1_HTML.jpg)
Pegylated interferons α2a and α2b in the treatment of chronic hepatitis C | Nature Reviews Gastroenterology & Hepatology
![Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41573-018-0011-2/MediaObjects/41573_2018_11_Fig2_HTML.png)
Interferons α and β in cancer: therapeutic opportunities from new insights | Nature Reviews Drug Discovery
![Pegylated interferon Peginterferon alfa-2b Peginterferon alfa-2a, Dopaminergic Pathways, pegylated Interferon, pegylation, pharmacodynamics png | PNGWing Pegylated interferon Peginterferon alfa-2b Peginterferon alfa-2a, Dopaminergic Pathways, pegylated Interferon, pegylation, pharmacodynamics png | PNGWing](https://w7.pngwing.com/pngs/856/955/png-transparent-pegylated-interferon-peginterferon-alfa-2b-peginterferon-alfa-2a-dopaminergic-pathways-pegylated-interferon-pegylation-pharmacodynamics.png)